Dermcidin is a novel biomarker of hepatic carcinoma?

6^th International Conference on Biomarkers & Clinical Research

August 31-September 02, 2015 Toronto, Canada

Fanghua Qiu

Guangzhou Hospital of Traditional Chinese Medicine, China

Scientific Tracks Abstracts: J Mol Biomark Diagn

Abstract :

We previously identified a group of Nck SH2 domain-binding proteins through a combination of GST-Nck1-SH2 pull down and 2DE in hepatic carcinoma (HCC) tissues, one of the proteins is Dermcidin (DCD). Western blot demonstrated DCD is overexpressed in HCC tissues and aggressive cell. To further identify potential blood-based biomarkers for the early detection of HCC cancer, we compare DCD level from HCC and healthy people, increased DCD was also detected with ELISA methods in 100 serum samples taken from HCC cancer diagnosis (p<0.001). In conclusion, these results present novel evidence that DCD levels may increase in early carcinogenesis, particularly among more aggressive forms of HCC cancer.

Biography :

Fanghua Qiu has completed her PhD from Guangzhou Medicine University. She has published 3 papers in reputed journals. She is currently working as an Associate Professor in Guangzhou Traditional Chinese Medicine Hospital, Guangzhou, China.

Email: qiufanghua1976@163.com